RNS Number : 7321N
Morgan Stanley Smith Barney LLC
01 October 2021
FORM
8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1.
KEY
INFORMATION
|
Nameofpersondealing
(Note
1)
|
Morgan Stanley Smith Barney LLC
|
|
Companydealtin
|
XERIS PHARMACEUTICALS INC
|
|
Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate
(Note2)
|
$0.001 COMMON STOCK
|
|
Date
of
dealing
|
30 September 2021
|
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security
dealt in (
Note 3)
|
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1)Relevantsecurities
|
12,388
|
0.02
|
0
|
0.00
|
|
(2)Derivatives (other than options)
|
0
|
0.00
|
0
|
0.00
|
|
(3)Options and agreements to purchase/sell
|
0
|
0.00
|
0
|
0.00
|
|
Total
|
12,388
|
0.02
|
0
|
0.00
|
| |
|
|
|
|
|
|
|
|
(b) Interests and short positions in relevant securities of the company, other than the
class dealt in (
Note 3
)
|
Class of relevant security:
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1)Relevantsecurities
|
0
|
0.00
|
0
|
0.00
|
|
(2)Derivatives (other than options)
|
0
|
0.00
|
0
|
0.00
|
|
(3)Options and agreements to purchase/sell
|
0
|
0.00
|
0
|
0.00
|
|
Total
|
0
|
0.00
|
0
|
0.00
|
| |
|
|
|
|
|
|
|
|
1.
DEALINGS
(Note
4)
(a) Purchases and sales
|
Purchase/sale
|
Number of relevant securities
|
Price per unit (Note 5)
|
|
SALE
|
160
|
2.3850 USD
|
|
SALE
|
629
|
2.4500 USD
|
|
SALE
|
29
|
2.4720 USD
|
(b) Derivatives transactions (other than options transactions)
|
Productname,
e.g.
CFD
|
Natureoftransaction
(Note
6)
|
Numberofrelevantsecurities
(Note
7)
|
Priceperunit
(Note
5)
|
|
N/A
|
N/A
|
N/A
|
N/A
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product
name,
e.g.
call
option
|
Writing,
selling,
purchasing,
varyingetc.
|
Number
of
securities
to
which
the
option
relates
(Note 7)
|
Exercise
price
|
Type,
e.g.
American,
Europeanetc.
|
Expiry
date
|
Option
money
paid/received
perunit
(Note 5)
|
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
(ii) Exercising
|
Productname,
e.g.
call
option
|
Numberofsecurities
|
Exercisepriceper unit
(Note
5)
|
|
N/A
|
N/A
|
N/A
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature
of
transaction
(Note
8)
|
Details
|
Price
per
unit
(if applicable)
(Note 5)
|
|
N/A
|
N/A
|
N/A
|
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
|
Fulldetailsofanyagreement,arrangementorunderstandingbetweenthepersondisclosing andanyotherpersonrelatingtothevotingrightsofanyrelevantsecuritiesunderanyoption referredtoonthisformorrelatingtothevotingrightsorfutureacquisitionordisposalofanyrelevantsecuritiestowhichanyderivativereferredtoonthisformisreferenced.Ifnone,this shouldbestated.
|
|
NONE
|
Is a Supplemental Form 8 attached?
(Note
9)
NO
|
Dateofdisclosure
|
01 October 2021
|
|
Contact
name
|
Craig Horsley
|
|
Telephone
number
|
+44 141 245-7736
|
|
If
aconnectedEFM,nameofofferee/offerorwithwhichconnected
|
N/A
|
|
If
aconnectedEFM,statenatureofconnection
(Note
10)
|
N/A
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
ISEMZMGGLMZGMZG